{"id":"NCT04005755","sponsor":"AFT Pharmaceuticals, Ltd.","briefTitle":"Maxigesic® IV Phase 3 Exposure Study","officialTitle":"A Phase 3, Open-Label, Multiple-Dose, Single-Arm Exposure Study of Maxigesic® IV in Patients With Acute Pain Following Orthopedic, General or Plastic Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-07-22","primaryCompletion":"2020-06-30","completion":"2020-07-07","firstPosted":"2019-07-02","resultsPosted":"2021-09-01","lastUpdate":"2021-09-01"},"enrollment":232,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Postoperative Pain"],"interventions":[{"type":"DRUG","name":"Maxigesic® IV","otherNames":[]}],"arms":[{"label":"Maxigesic® IV","type":"EXPERIMENTAL"}],"summary":"The study aims to determine the tolerability of repeated doses of Maxigesic® IV over an extended period of exposure.","primaryOutcome":{"measure":"Incidence of TEAEs (Treatment-emergent Adverse Events)","timeFrame":"During treatment period (≥ 48 hours - 5 days)","effectByArm":[{"arm":"Maxigesic® IV","deltaMin":256,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":16},"locations":{"siteCount":4,"countries":["United States","New Zealand"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":232},"commonTop":["Infusion site pain","Nausea","Infusion site extravasation","Constipation","Headache"]}}